topper's finally got some new material, page-28

undervalued profitable sirtex This is one of the most undervalued ,underfollowed biotechs on the ASX with an FDA approved product that has turned the corner up and had recently reported yearto year 123% + growth and will be benefitting from 9 additional US centers where the Sirtex product is sold. Expecting also expanding uses for product, more expanding centers, and more profitable contracts with Pfizer and Sanofi who are both doing trials with their chemo drugs with Sirtex product for more growth. AT $2.10 ,HH says worth north of $ 5 currently. Do your own work and see www.sirtex.com. Expecting analysts to jump on bandwagon after train leavs the station.